Hundreds of Albertans Call on Jason Kenny to Save Canceled Treatment Program
Call to Maintain Funding for Alberta’s Injectable Opioid Agonist Treatment Clinics
The injection room of the iOAT program in Edmonton. This highly effective program is slated to close in March 2020.
An open letter to the Government of Alberta Honourable Jason Kenney, Premier
Cc: Honourable Tyler Shandro, Minister of Health, Alberta Honourable Jason Luan, Associate Minister for Mental Health and Addictions David Shepherd, MLA, Opposition Critic for Health Heather Sweet, MLA, Opposition Critic for Mental Health and Addictions Dr. Deena Hinshaw, Chief Medical Officer of Health Honourable Patty Hajdu, Minister of Health, Canada
Dear Premier Kenney,
We, the undersigned are a group of Albertan patients, families, physicians, nurses, pharmacists, social workers, counsellors, peer workers, academics, and concerned citizens of the province. We are writing to express our grave concerns with your government’s decision to discontinue funding for Edmonton and Calgary’s injectable opioid agonist treatment (iOAT) programs after March 2021. Many of us have experience providing iOAT. Some of us and our families have directly benefited from receiving this life-saving treatment. All of us understand the need for iOAT as part of the full spectrum of care for people as they recover from the impacts of opioid use disorders and have been encouraged by the remarkable health and social benefits of this treatment to the people who receive it, to their families, and to the community at large.
While much of the health care system’s attention has turned towards protecting Albertans through the global COVID-19 pandemic, we also recognize that people at risk of severe adverse outcomes from substance use disorders are at the intersection of both the pandemic and the opioid overdose crisis which continues to exact its toll on communities across Canada. Alberta remains one of the hardest hit provinces with close to two people dying daily as a result of accidental opioid poisoning (1) and reports of increasing EMS calls for overdose (2) and the re-emergence of carfentanil in the drug supply3 make us concerned that this crisis has worsened over recent months. At this time more than any before, we must offer all evidence-based treatments to patients. The decision to discontinue funding to iOAT makes this option inaccessible for Albertans who may seek help as the programs are no longer able to accept new patients. Those who are currently benefiting from this treatment will be forced off of it in the coming months and many of these individuals may suffer severe adverse outcomes as a result.
In September 2019, the Canadian Research Initiative in Substance Misuse (CRISM) published National Guidelines on iOAT for Opioid Use Disorder. National experts thoroughly reviewed scientific evidence to develop these guidelines which were subject to expert peer review. The guidelines are clear: iOAT is a necessary treatment option for individuals with severe injection opioid use disorders that have not responded to other treatments (4). Benefits demonstrated through scientific study include reduced illicit opioid use, improved retention in treatment and health care, reduced criminal involvement and incarceration, reduced mortality, and improved overall health and social functioning (5-8). Furthermore, studies in both Europe and Canada have consistently proven that iOAT is cost effective given the significant reductions in criminal activity (9-11) and hospitalizations (12) with their associated costs.
The National Guideline on iOAT for Opioid Use Disorder is also clear that iOAT should not be discontinued while a patient continues to benefit from treatment. Decisions to transition to other treatment options should only be made in collaboration with the patient and based on thorough risk-benefit assessments. Discontinuing funding for the programs removes that opportunity and forces their health care providers to practice against national expert guidance. Patients who have developed trusting relationships with these programs will be disengaged once again and many may not avail themselves of other treatments that have failed them before. These prospects are tragic as patients will be at tremendous risk of destabilization and related harms, including overdose mortality.
The iOAT programs in Edmonton and Calgary are benchmarks of what an intensive, multidisciplinary, and comprehensive addiction treatment program can offer for individuals at critical periods in the trajectory of their recovery. Their patients have access to not only life-saving medication treatment from physicians and nurse practitioners but are also supported in their recovery by peer workers, mental health resources, social workers, nurses, pharmacists, and primary care. Albertans can be proud of what these clinics have accomplished and the positive impacts on their communities. With ongoing support and funding, they could no doubt continue to thrive, support recovery, and offer hope to highly vulnerable patients. Premier, please do not end this evidence-based, cost effective treatment in Alberta. We call on the Government of Alberta to reverse its decision to discontinue funding to the Edmonton and Calgary Injectable Opioid Agonist Treatment Clinics and to continue to support this critical treatment option for Albertans.
Sincerely,
References:
1. Health, Government of Alberta, June 2020, Alberta Opioid Response Surveillance Report: Q1 2020. https://www.alberta.ca/opioid-reports.aspx
2. https://www.cbc.ca/news/canada/edmonton/drug-users-warned-of-dangers-after-spike-in-opioid-related-ems-calls-in-edmonton-1.5600260
3. https://edmontonjournal.com/news/local-news/spike-in-carfentanil-deaths-opioid-overdoses-in-edmonton-prompts-health-warning
4. Canadian Research Initiative in Substance Misuse (CRISM). National Injectable Opioid Agonist Treatment for Opioid Use Disorder Clinical Guideline. Published September 23, 2019. https://crism.ca/projects/ioat-guideline/
5. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews. 2011(12). 10.1002/14651858.CD003410.pub4
6. Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. The British Journal of Psychiatry. 2015;207(1):5-14. 10.1192/bjp.bp.114.149195
7. Oviedo-Joekes E, Guh D, Brissette S, et al. Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry. 2016;73(5):447-455. 10.1001/ jamapsychiatry.2016.0109
8. Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. New England Journal of Medicine. 2009;361(8):777-786. doi:10.1056/NEJMoa0810635
9. Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012;184(6):E317-328. 10.1503/cmaj.110669
10. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. The British journal of psychiatry : the journal of mental science. 2013;203(5):341-349. 10.1192/bjp.bp.112.111583
11. Byford S, Barrett B, Metrebian N, et al. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. The British journal of psychiatry : the journal of mental science. 2013;203(5):341-349. 10.1192/bjp.bp.112.111583
12. Bansback N, Guh D, Oviedo-Joekes E, et al. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction. 2018;113(7):1264-1273. 10.1111/ add.14171